Pfizer says its antiviral pill slashes risk of severe Covid-19 by 89%
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Monday
August 08, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
MONDAY, AUGUST 08, 2022
Pfizer says its antiviral pill slashes risk of severe Covid-19 by 89%

Coronavirus chronicle

Reuters
05 November, 2021, 05:15 pm
Last modified: 06 November, 2021, 11:15 am

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children aged 5-12 yrs to get Pfizer vaccine 
  • US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016

Pfizer says its antiviral pill slashes risk of severe Covid-19 by 89%

The data has not yet been published or peer-reviewed, but Pfizer said in a news release that it would submit the data to regulators “as soon as possible

Reuters
05 November, 2021, 05:15 pm
Last modified: 06 November, 2021, 11:15 am
 A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters
A 3D printed Pfizer logo is placed near medicines from the same manufacturer in this illustration taken September 29, 2021. Photo :Reuters

* Trial stopped early after high success rate

* Results appear to surpass those of rival Merck drug

* Pfizer to submit interim data to FDA before Nov. 25 


Pfizer Inc's experimental antiviral pill to treat Covid-19 cut by 89% the chance of hospitalization or death for adults at risk of severe disease, the company said on Friday, as its CEO vowed to make this promising new weapon in the fight against the pandemic available globally as quickly as possible.

The trial's results suggest that Pfizer's drug surpasses Merck & Co Inc's pill, molnupiravir, which was shown last month to halve the chance of dying or being hospitalized for Covid-19 patients at high risk of serious illness.

Pfizer's pill, with the brand name Paxlovid, could secure US regulatory approval by the end of the year. Pfizer said it plans to submit interim trial results to the Food and Drug Administration (FDA) before the Nov. 25 US Thanksgiving holiday. The trial was stopped early due to its high success rate.

President Joe Biden said the US government has secured millions of doses of Pfizer's drug.

"If authorized by the FDA we may soon have pills that treat the virus in those who become infected," Biden said. "The therapy would be another tool in our toolbox to protect people from the worst outcomes of Covid."

Shares in Pfizer, which also makes one of the mostly widely used Covid-19 vaccines, rose 11% to close at $48.61. Merck's fell 10% to close at $81.61. Shares of vaccine makers took a hit, with Moderna Inc, Pfizer's German partner BioNTech SE and Novavax all down 11-21%.

Pfizer's pill is given in combination with an older antiviral called ritonavir. The treatment consists of three pills given twice daily. It has been in development for nearly two years.

The Pfizer and Merck pills are eagerly anticipated, with only limited options currently available for treating people sick with Covid-19. Full trial data is not yet available from either company.

Pfizer is in active discussions with 90 countries over supply contracts for its pill, Chief Executive Officer Albert Bourla said in an interview.

"Our goal is that everyone in the world would be able to have it as quickly as possible," Bourla said.

Bourla added that for high-income countries Pfizer expects to price its treatment close to where Merck has priced its drug. Merck's US contract price is around $700 for a five-day course of therapy. For low-income countries, Bourla said Pfizer is considering several options, with the goal of "no barrier for them as well to have access."

Merck's pill was approved by British regulator in a world first on Thursday.

Even with the potential offered by the Pfizer and Merck pills, preventing Covid-19 infections through broad use of vaccines remains the best way to control a pandemic that has killed more than 5 million people worldwide, including more than 750,000 in the United States, infectious disease experts said.

"Vaccines are going to be the most effective and reliable tool that we have in this pandemic," said Dr. Grace Lee, professor of pediatrics at Stanford University School of Medicine. "These oral medications are going to augment our ability to really reduce the risk of severe disease, hospitalization and death, which is huge, but it won't prevent infection."

While more than 7 billion vaccine doses have been administered worldwide, that has covered only about half the world's people. In the United States, 58% of all people, including 70% of adults, are fully vaccinated.

Mizuho analyst Vamil Divan forecast a "very minor impact" from Pfizer's drug on vaccination among people who do not want the vaccine or a booster shot as recommended by US health regulators.

"I think there's a small percentage of people that may decide not to get vaccinated now that there are good treatment options," Divan said.

MANUFACTURING GOALS

Pfizer said it expects to manufacture 180,000 treatment courses by the end of this year and at least 50 million courses by the end of next year, including 21 million in the first half of 2022. Bourla said that, based on the better-than-expected trial results, Pfizer is considering potentially doubling next year's manufacturing target.

Antivirals need to be given as early as possible, before an infection takes hold, to be most effective.

The planned analysis of 1,219 patients in Pfizer's study examined hospitalizations or deaths among people diagnosed with mild to moderate Covid-19 with at least one risk factor for developing severe disease, such as obesity or older age.

Among those given Pfizer's drug within three days of symptom onset, the pill lowered the chances of hospitalization or death for adults at risk of developing severe Covid-19 by 89% compared to those receiving a placebo. Among these patients, 0.8% were hospitalized and none died by 28 days after treatment, compared to a 7% hospitalization rate and seven deaths in the placebo group.

Rates were similar for patients treated within five days of symptoms: 1% of the treatment group was hospitalized, compared to 6.7% for the placebo group, which included 10 deaths. Pfizer said that represents 85% effectiveness at preventing hospitalization or death.

Two other trials - one in people without underlying risk factors and another in people who have been exposed to the virus but are not yet infected - are continuing, with those results likely be available in the first quarter of 2022, Bourla said.

Pfizer did not detail side any effects but said adverse events happened in about 20% of both treatment and placebo patients. Possible side effects include nausea and diarrhea.

Top News / World+Biz

Pfizer / Pfizer coronavirus vaccine / Pfizer Covid-19 Vaccine / Pfizer Inc

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Denim industry banks on new tech for further leap
    Denim industry banks on new tech for further leap
  • TBS file photo
    Now 99% Bangladesh products come under China’s duty-free offer
  • Picture: Collected
    The six billion dollar man

MOST VIEWED

  • People line up for nucleic acid tests during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 26, 2022. REUTERS/Aly Song
    China's Sanya holiday hotspot shuts duty-free malls, venues to curb Covid
  • FILE PHOTO: People wearing protective face masks walk amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea May 15, 2020, in this photo released by Kyodo. Mandatory credit Kyodo/via REUTERS
    North Korea marks end of first Covid wave, but risks persist
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    South Africa reports first death causally linked to Covid vaccine
  • 'Living with Covid': Where the pandemic could go next
    'Living with Covid': Where the pandemic could go next
  • A worker, wearing a protective suit following the coronavirus disease (COVID-19) outbreak, transports luggage on the tarmac of Wuhan Tianhe International Airport, on a hot summer day in Wuhan, Hubei province, China July 14, 2022. cnsphoto via REUTERS
    China's Wuhan locks down 1m residents amid new Covid cases
  • Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel
    Covid: CDC flags Bangladesh and 5 other countries as ‘high risk’ for travel

Related News

  • BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • Children aged 5-12 yrs to get Pfizer vaccine 
  • US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
  • Pfizer says 3 Covid shots protect children under 5
  • Cash-rich Pfizer to pay $11.6 bln for Biohaven in biggest deal since 2016

Features

Deeply depressed and afraid of living in total darkness, the Noakhali-based housewife Rasheda desires nothing but to get her vision back. Photo: Noor-A-Alam

Blind people need 25,000 corneas. Sandhani gets around 25

54m | Panorama
Picture: Collected

The six billion dollar man

1h | Panorama
Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

Safa Shareef’s bridal make-up: Contemporary with a ‘deshi’ touch

23h | Mode
Infograph: TBS

Why a drastic fuel price hike is dangerous

1d | Panorama

More Videos from TBS

Is smartphone use reducing our memory?

Is smartphone use reducing our memory?

24m | Videos
City dwellers in trouble due to lack of public transport

City dwellers in trouble due to lack of public transport

24m | Videos
Oil prices fall due to recession fears

Oil prices fall due to recession fears

29m | Videos
Small business owners in a tight spot due to commodity price hike

Small business owners in a tight spot due to commodity price hike

29m | Videos

Most Read

1
Diesel price hiked by Tk34 per litre, Octane by Tk46
Energy

Diesel price hiked by Tk34 per litre, Octane by Tk46

2
Housing projects sprouting up by Dhaka-Mawa expressway
Real Estate

Housing projects sprouting up by Dhaka-Mawa expressway

3
July remittance hits two-year high
Economy

July remittance hits two-year high

4
Infographic: TBS
Banking

Dollar rate will be left to market after two months: Governor

5
Bangladesh to resume talks for Ukrainian wheat import
Economy

Bangladesh to resume talks for Ukrainian wheat import

6
A liquefied natural gas (LNG) tanker is tugged towards a thermal power station in Futtsu, east of Tokyo, Japan November 13, 2017. REUTERS/Issei Kato/File Photo
Energy

Summit proposes long-term LNG supply to Petrobangla

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net